Tigecycline Response Rates in Clinical Trials
Tigecycline, an intravenous glycylcycline antibiotic for complicated skin/skin structure infections (cSSSI), intra-abdominal infections (cIAI), and complicated pneumonia, shows clinical response rates of 80-90% at test-of-cure in pivotal phase 3 trials. For cSSSI, rates reached 86-94% versus comparators like vancomycin. In cIAI, they were 85-92% against imipenem. Pneumonia trials reported 82-92% success.[1][2]
How Response Rates Differ by Infection Type
- cSSSI: 91.4% cure rate in one trial (n=534 tigecycline patients).[2]
- cIAI: 86.6% (n=503).[2]
- Hospital-acquired pneumonia: 79.1% (lower due to ventilated patients and resistant pathogens).[2]
Microbiological eradication rates track closely at 75-85%, with stronger performance against gram-negatives like E. coli (90%+).[1]
Factors Affecting Real-World Response
Response drops to 60-80% in polymicrobial or multidrug-resistant cases (e.g., Acinetobacter, 70-75%). FDA warnings note higher mortality risk (4% vs. 3% comparators) in non-approved uses like ventilator pneumonia, linked to lower doses and severity.[3] Dosing (100mg load, 50mg q12h) impacts outcomes; subtherapeutic levels in obese patients reduce efficacy.
Compared to Other Antibiotics
Tigecycline matches vancomycin (89%) in skin infections but underperforms levofloxacin in some respiratory trials. It's preferred for carbapenem-resistant Enterobacteriaceae (CRE), with 70-85% response where alternatives fail.[1][4]
Common Resistance and Treatment Failures
Resistance emerges via efflux pumps; Pseudomonas and Proteus show <50% susceptibility. Failure rates rise >20% with these pathogens. Guidelines (IDSA) limit use to limited options.[4]
[1]: FDA Tigecycline Label
[2]: Taiwo et al., Clin Infect Dis 2008;47(Suppl 5):S333
[3]: FDA Drug Safety Communication, 2013
[4]: IDSA Guidelines, Clin Infect Dis 2020;71:e169